PT-141 Storage and Stability: What Studies Report

The short version

Two questions dominate searches on this topic: whether PT-141 requires refrigeration, and how long a reconstituted solution remains usable. The honest answer from the published record is that neither question has been answered in a peer-reviewed stability study of this specific peptide. The bremelanotide literature summarised below consists of pharmacology reviews, randomized trials and safety analyses — not analytical chemistry or shelf-life work. The approved injectable product carries storage conditions in its manufacturer labeling, which is a regulatory document rather than a journal article. Everything else on this page is general peptide handling chemistry, presented as background and labelled as such.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, medication or product. Nothing here describes how any individual should handle, prepare or administer anything.

What PT-141 (bremelanotide) is

PT-141 is the development code for bremelanotide, a synthetic melanocortin receptor agonist. An early review described PT-141 as a melanocortin agonist investigated for sexual dysfunction, derived from the melanocortin peptide family rather than from the vasodilator drug classes used in erectile dysfunction at the time (PMID 12851303). A later neurobiology review described the compound as acting on central melanocortin pathways involved in sexual desire (PMID 33455598).

Chemically, bremelanotide is a cyclic peptide built on the core recognition sequence of α-melanocyte-stimulating hormone. Two structural features matter for stability discussions. First, the molecule is cyclised rather than fully linear, and cyclisation generally reduces conformational freedom and exopeptidase access compared with an open-chain peptide of similar length. Second, the sequence carries a norleucine residue in the position occupied by methionine in native α-MSH; norleucine lacks the sulphur atom that makes methionine a common oxidation site in peptide drugs. The molecule does retain tryptophan, an aromatic residue that is among the more photolabile and oxidation-sensitive amino acids in peptide pharmaceuticals.

Bremelanotide received regulatory approval in 2019 for acquired, generalised hypoactive sexual desire disorder in premenopausal women, as summarised in a first-approval report (PMID 31429064). Two randomized phase 3 trials evaluated bremelanotide 1.75 mg administered subcutaneously on an as-needed basis (PMID 31599840). An open-label extension reported longer-term safety and efficacy data in women who continued in the program (PMID 31599847).

Why no bremelanotide stability study appears here

Formulation and stability data for approved injectables usually live in regulatory submissions, manufacturer labeling and internal quality documentation rather than in the clinical journals that index on PubMed. The published bremelanotide papers — the approval summary (PMID 31429064), the pharmacotherapy evaluation (PMID 36242769) and the drug-approval commentary (PMID 31893927) — describe indication, mechanism, trial results and adverse events. None of them reported shelf-life testing, forced degradation, freeze-thaw cycling or photostability results for the molecule.

A second point often missed in online discussion: the approved product is a manufactured, pre-filled, single-dose subcutaneous injection. It is not reconstituted from a powder by the end user. Questions about "how long a reconstituted vial lasts" therefore do not map onto the approved medicine at all; they map onto unapproved research-use-only lyophilised powders, for which no manufacturer has published stability data and no regulatory body has assigned a beyond-use date.

Lyophilized versus reconstituted: the general chemistry

Across peptide pharmaceuticals as a class, the difference between a dry cake and a solution is the single largest determinant of degradation rate. Water is a reactant in several of the main peptide degradation pathways, and it also acts as a plasticiser that increases molecular mobility. Freeze-drying removes most of that water and immobilises the peptide in an amorphous glass, which is why most peptide drug products that cannot be stabilised in solution are supplied lyophilized.

The degradation routes commonly described for peptides in aqueous solution include:

• Hydrolysis of amide bonds, accelerated at extremes of pH and by elevated temperature.
• Deamidation of asparagine and glutamine residues, one of the most frequent solution-phase changes in peptide drugs and strongly pH-dependent.
• Oxidation of susceptible residues — methionine, cysteine, tryptophan, tyrosine and histidine — driven by dissolved oxygen, trace metals and light.
• Aggregation and precipitation, often nucleated at interfaces such as the air–liquid boundary or a container wall.
• Adsorption of peptide onto glass, plastic or filter surfaces, which lowers solution concentration without producing any visible change.

In the dry state, these routes are slowed but not abolished. Residual moisture in a lyophilized cake still permits deamidation and hydrolysis over long periods, and solid-state aggregation can occur if the cake is exposed to humidity or if the glass transition temperature of the formulation is exceeded during storage.

Temperature

Temperature dependence of chemical degradation is conventionally modelled with Arrhenius kinetics, meaning that reaction rates rise steeply rather than linearly as temperature increases. For peptide products this is the basis of cold-chain distribution and of accelerated stability testing, in which samples are held at elevated temperature to project shelf life at the intended storage condition. Internationally harmonised stability guidelines define long-term, intermediate and accelerated storage conditions for this purpose, and manufacturers use them to justify the storage statement printed on the label.

The practical consequence is that no general rule such as "peptides must be refrigerated" holds across the class. Some peptide products are labelled for refrigerated storage, some for controlled room temperature, and some tolerate excursions for defined periods — the answer depends on the specific formulation, its excipients, its buffer and its container closure. For any approved product, including the bremelanotide injection described in the approval literature (PMID 31429064), the authoritative storage statement is the one on the manufacturer's labeling, not an extrapolation from other peptides.

Freeze–thaw

Freezing is not a neutral act for a peptide solution. As ice forms, solutes concentrate in the shrinking unfrozen fraction, buffer components can crystallise preferentially and shift local pH, and a large ice–water interface is created where surface-active molecules can unfold or aggregate. Repeated freeze–thaw cycling is therefore used as a deliberate stress test in pharmaceutical development, and cycling studies typically report cumulative effects that a single freeze does not produce. Cryoprotectants and bulking agents such as sugars and polyols are added to formulations specifically to mitigate these interfacial and concentration stresses.

Light

Photostability is assessed separately from thermal stability in pharmaceutical development because the mechanisms differ. Ultraviolet and short-wavelength visible light can excite aromatic residues directly or generate reactive oxygen species through photosensitisers present as trace impurities. Tryptophan and tyrosine are the residues most often implicated, and photo-oxidation products of tryptophan are well described in the protein chemistry literature. Amber vials, secondary cartons and foil overwraps exist in pharmaceutical packaging for exactly this reason.

Container, closure and surface effects

Peptides can adsorb to borosilicate glass, to polypropylene and to the silicone oil used to lubricate syringe barrels, and they can interact with elastomeric stoppers. Low concentrations are the most vulnerable, because a fixed amount of surface loss removes a larger fraction of the total. Formulators counter this with surfactants, carrier proteins in research settings, or container materials selected during development. Leachables and extractables from stoppers and plungers are separately evaluated during product development because they can catalyse oxidation.

Beyond-use dating: what the compendial framework covers

In the United States, beyond-use dates for compounded sterile preparations are governed by compendial chapters that assign dating according to the sterility risk category of the preparation and the storage temperature, not according to the chemical stability of the particular molecule. Those frameworks apply to preparations made in licensed pharmacies under defined conditions. They do not generate a beyond-use date for a research-use-only powder handled outside that system, and they are not a statement that a given peptide remains chemically intact for the dating period. Chemical stability and microbiological beyond-use dating are two separate questions, and a solution can be sterile while a meaningful fraction of the peptide has degraded, or chemically intact while contaminated.

Research-use-only labeling is itself a regulatory status: it signals that the material has not been evaluated for human use and that no agency has reviewed its identity, purity, potency or stability. This page does not offer legal advice.

Product quality, degradation and safety: What Studies Report

The safety picture for bremelanotide in the published literature comes from trials that used manufactured, quality-controlled drug product. A pooled analysis across the clinical development program reported nausea, flushing and headache as the most common adverse events, with most classed as mild or moderate, and reported injection-site reactions among the observed events (PMID 35147466). The two phase 3 trials also reported nausea, flushing and headache as the leading adverse events with bremelanotide 1.75 mg subcutaneously (PMID 31599840), and the open-label extension reported a consistent tolerability profile over longer exposure (PMID 31599847). Researchers in these programs were characterising a defined product; none of these safety datasets speaks to material of unverified identity, purity or storage history, and degradation products or impurities were not the subject of these reports.

Efficacy interpretation has itself been contested. A review in a neurology journal summarised the evidence supporting the indication (PMID 35076581), while re-analyses of the phase 3 data reported that the magnitude of benefit was small (PMID 33678061), a position echoed in a later critical appraisal that questioned the clinical meaningfulness of the outcomes reported (PMID 36809187) and in a bulletin commentary on regulatory precedent (PMID 34642243).

Limits of this summary

The general chemistry described above is drawn from established peptide formulation science and is presented as background, not as a finding about bremelanotide. No stability study of PT-141 is cited here because none appears in the verified clinical literature reviewed for this page. Where a specific storage condition matters, the applicable sources are the manufacturer's labeling for an approved product and a licensed clinician or pharmacist — not generalisation from other peptides, and not this page.

References

• Bremelanotide: First Approval (Drugs, 2019)
• Bremelanotide for Treatment of Female Hypoactive Sexual Desire (Neurology International, 2022)
• Safety Profile of Bremelanotide Across the Clinical Development Program (Journal of Women's Health, 2022)
• An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder (Expert Opinion on Pharmacotherapy, 2023)
• The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women (CNS Spectrums, 2022)
• Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women (Journal of Sex Research, 2021)
• Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent (Drug and Therapeutics Bulletin, 2021)
• Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder (Journal of Sex Research, 2024)
• Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder (Annals of Pharmacotherapy, 2020)
• Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (Obstetrics and Gynecology, 2019)
• Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder (Obstetrics and Gynecology, 2019)
• PT-141: a melanocortin agonist for the treatment of sexual dysfunction (Annals of the New York Academy of Sciences, 2003)